ACRP Announces TransCelerate's Intentions to Accept its Certification
Clinical research professionals who have a current CPI or CCRC designation will be able to use that as evidence that retaking GCP training is not necessary if they are working on a trial for one of the TransCelerate companies.
The ACRP announced that TransCelerate BioPharma is accepting its affiliate’s certifications for Certified Clinical Research Coordinator (CCRC®) and Certified Physician Investigator (CPI®) as evidence of Good Clinical Practice (GCP) training.
That TransCelerate’s membership companies are accepting these certifications to eliminate redundant GCP training for each and every new study team the coordinators or investigators join is not a surprise. This initiative to create efficiencies in the clinical trials process was one of the original five targets set forth in TransCelerate’s formation. Specifically, at that time it said of Site Qualification and Training , its goal was “To build upon the creation of common criteria for mutual recognition of GCP training and common forms to collect generic information about study sites, TransCelerate will provide a common framework to streamline the process for qualifying investigator sites, and standardizing non-protocol specific forms for clinical trials. The organization will also establish criteria for training site personnel new to clinical research and trials.”
The ACRP affiliate--the Academy of Clinical Research Professionals (the Academy)--have produced more than 28,500 certificants in more than 60 countries since 1992 (including the CPI, CCRC, and Certified Clinical Research Associate [CCRA®] programs.
At posting time, TransCelerate had not yet posted its release or comments. You can read the ACRP's full release here.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
